Citations

Citations to this article as recorded by  

• Efficacy and safety of adding a fourth oral antidiabetic drug versus metformin dose escalation in patients with type 2 diabetes inadequately controlled on triple oral combination therapy (EFFORT): A 24‐week, randomized, open‐label, multicenter trial
  So Ra Kim, Jun Hwa Hong, Sin Gon Kim, Soo‐Kyung Kim, Hyuk‐Sang Kwon, Jun Sung Moon, Jung Hwan Park, Jae Myung Yu, Bong‐Soo Cha, Byung‐Wan Lee
  Diabetes, Obesity and Metabolism.2026; 28(4): 3305.     CrossRef
• Contemporary Type 2 Diabetes Guidelines: Converging Evidence, Diverging Strategies, and the Position of the Korean Diabetes Association Framework
  Suk Kyeong Kim, Dong-Lim Kim, Keeho Song, Shinae Kang, Byung-Wan Lee, Jong Han Choi
  Endocrinology and Metabolism.2026; 41(3): 351.     CrossRef
• Association of SGLT2 Inhibitor Use with Glycosuria, Pyuria, Urinary Symptoms, and Significant Urine Culture Positivity in Adults with Type 2 Diabetes: A Prospective Cross-Sectional Study
  Türkan Tüzün, Ayten Eraydın
  Medicina.2026; 62(9): 1721.     CrossRef
• 2025 Clinical Practice Guidelines for Diabetes Management in Korea: Recommendation of the Korean Diabetes Association
  Shinae Kang, Seon Mee Kang, Jong Han Choi, Seung-Hyun Ko, Bo Kyung Koo, Hyuk-Sang Kwon, Mi Kyung Kim, Sang Yong Kim, Soo-Kyung Kim, Young-eun Kim, Eun Sook Kim, Jae Hyeon Kim, Chong Hwa Kim, Ji Min Kim, Hae Jin Kim, Min Kyong Moon, Sun Joon Moon, Jun Sung
  Diabetes & Metabolism Journal.2025; 49(4): 582.     CrossRef
• Synergism of Synthetic Sulfonamides and Natural Antioxidants for the Management of Diabetes Mellitus Associated with Oxidative Stress
  Ancuța Dinu (Iacob), Luminita-Georgeta Confederat, Ionut Dragostin, Ionela Daniela Morariu, Dana Tutunaru, Oana-Maria Dragostin
  Current Issues in Molecular Biology.2025; 47(9): 709.     CrossRef
• 2025 Clinical Practice Guidelines for Diabetes: Pharmacological Treatment of Type 2 Diabetes
  Jong Han Choi
  The Journal of Korean Diabetes.2025; 26(3): 158.     CrossRef
• Bridging Evidence and Practice: A Consensus Statement from the Korean Diabetes Association on Diabetes Screening, Pharmacological Treatment and Severe Diabetes
  Jong Han Choi, Shinae Kang, Soo-Kyung Kim, Won Jun Kim, Ji Min Kim, Jaehyun Bae, Jae-Seung Yun, Eonju Jeon, Young-Eun Kim, Jae Hyun Bae, Hun Jee Choe, Young Min Cho, Seung-Hyun Ko, Sang Yong Kim, Hae Jin Kim, You-Cheol Hwang, Min Kyong Moon, Suk Chon, Seo
  Diabetes & Metabolism Journal.2025; 49(6): 1155.     CrossRef

Citations

Citations to this article as recorded by  

• Glycemia Risk Index is Associated With Risk of Albuminuria Among Individuals With Type 1 Diabetes
  Ji Yoon Kim, Jee Hee Yoo, Nam Hoon Kim, Jae Hyeon Kim
  Journal of Diabetes Science and Technology.2026; 20(3): 775.     CrossRef
• Sodium‐glucose cotransporter 2 inhibitor ameliorates thiazolidinedione‐induced fluid retention through vascular leakage reduction in white adipose tissue
  Ji Yoon Kim, Hye‐Min Jang, Hye‐Jin Lee, Ah Hyeon Lee, Dong‐Hoon Kim, Sin Gon Kim, Nam Hoon Kim
  Diabetes, Obesity and Metabolism.2026; 28(3): 1764.     CrossRef
• Development and Validation of a High‐Performance Liquid Chromatography Coupled With Photodiode Array Detection Method for the Simultaneous Analysis of Metformin, Cyanoguanidine, and Antidiabetic Agents in Fixed‐Dose Combinations
  Gökhan Bayrak, Selen Al, Aykut Kul, Armağan Önal
  SEPARATION SCIENCE PLUS.2026;[Epub]     CrossRef
• Ethnic Disparities in Glycemic Control among Malaysian Adults with Type 2 Diabetes: A Retrospective Multivariable Analysis
  Fikry Ahmad, Suhaili Abubakar, Sharifah Sakinah Syed Alwi, Ng Ooi Chuan, Hasni Idayu Saidi
  Journal of Racial and Ethnic Health Disparities.2026;[Epub]     CrossRef
• GLIMSI: A real-world, multicenter study assessing the effectiveness and safety of Sitagliptin + Glimepiride + Metformin FDC in Indian patients with Type 2 diabetes
  Kunal Zaveri, Girish Kulkarni, Rathish Nair, Govarthanan Shanmugan, Shubhada Amol Dharmadhikari, R. P. S. Makkar, Rahul Jalgaonkar, B. D. Chatterjee, Krishnaprasad Korukonda, Natural Hoi Sing Chu
  PLOS One.2026; 21(2): e0337107.     CrossRef
• A Randomized, Multicenter Study Evaluating the Efficacy, Safety and Tolerability of Dapagliflozin + Gliclazide Fixed Dose Combination Over Dapagliflozin Monotherapy in Type 2 Diabetes Mellitus Patients Inadequately Controlled on Metformin Monotherapy
  Suhas G Erande, Amar Raykantiwar, Vivek Shejole, Rashmi GR, Animesh Maiti, A.S. Veeramani Kartheek, Mohamed Hanifah, Richa Giri, Sharvil Gadve, Arindam Ray, Kunal Thakkar, Balram Sharma, Saket Kant, Abhyudaya Verma , Yogesh Yadav, Hiren Prajapati, Honey D
  Cureus.2026;[Epub]     CrossRef
• Comparative Analysis of Clinical Outcomes in Patients With Type 2 Diabetes Mellitus on Monotherapy Versus Combination Therapy
  Hariballav Mahapatra, Piyush Kumar Gupta, Ajo Paul, Amit Nampalliwar, Manju Bansal, Baijnath Das, K. Parameswaran Namboothiri
  Cureus.2026;[Epub]     CrossRef
• Clinical Experience and Outcomes with Triple-drug Fixed-dose Combination Therapy (Sitagliptin + Dapagliflozin + Metformin Sustained-Release Tablets) in Type 2 Diabetes Mellitus Management: A Real-world Observational Survey of Clinician Perspectives
  Manoj Arajanbhai Suva
  Archives of Medicine and Health Sciences.2026; 14(1): 61.     CrossRef
• Circulating GDF15 levels reflect metabolic and inflammatory burden in early dysglycemia: findings from the ADIOS cohort
  Ji Yoon Kim, Ah Hyeon Lee, Jiyoon Lee, Hye-Min Jang, Sin Gon Kim, Dong-Hoon Kim, Nam Hoon Kim
  Diabetes Research and Clinical Practice.2026; 239: 113461.     CrossRef
• A Phase III, Randomized, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of a Fixed Dose Combination of Dapagliflozin and Pioglitazone in Type 2 Diabetes Mellitus Patients Inadequately Controlled on Metformin Monotherapy
  Nilakshi Deka, Sambit Das, Kirtikumar D. Modi, Arundhati Das Gupta, Mukulesh Gupta, Ajay Chhabra, Niroj Kumar Mishra, Manjunath Goroshi, Hemi Soneja, Sameer Agarwal, Biplab Mandal, Amarkant Amar, Santosh Saklecha, Hiren Prajapati, Sachin Negi
  International Journal of Diabetes and Technology.2026; 5(3): 146.     CrossRef
• Safety outcomes of antidiabetic medications: A comprehensive review of the EU summaries of product characteristics and international clinical practice guidelines
  David Liang, Daniala L. Weir, Safana Thevasahayam, Vera H. M. Deneer, Arno Siebes, Helga Gardarsdottir
  British Journal of Clinical Pharmacology.2026;[Epub]     CrossRef
• Early combination therapy in type 2 diabetes: Rethinking initial treatment strategies
  Andrej Janez, Tanja Smid, Manfredi Rizzo, Tsvetalina Tankova
  Journal of Diabetes and its Complications.2026; 40(10): 109392.     CrossRef
• GDD, a first-in-class APPL1 activator, restores mitochondrial homeostasis and insulin sensitivity with regulation of LKB1-AMPK axis
  Hao Zheng, Ya-Ru Zhao, Xian-Yan Deng, Dan-Yu Huang, Fang-Qiong Qiu, Chang Yan, Shu-Ying Li, Jing Chen, Wan-Bin Song, Hui-Qing Lv, Ri-Hui Wu, Ligen Lin, Li-She Gan
  Phytomedicine.2026; 161: 158712.     CrossRef
• Beyond Fat Loss: Addressing the Sarcopenia Challenge of Incretin-Based Therapies
  Ji Yoon Kim, Nam Hoon Kim
  Diabetes & Metabolism Journal.2026; 50(5): 844.     CrossRef
• Real-world effectiveness of quadruple oral hypoglycemic therapy in type 2 diabetes patients refusing insulin therapy
  Han-Sang Baek, Chaiho Jeong, Tae-Seo Sohn, Hyun Shik Son
  BMC Endocrine Disorders.2026;[Epub]     CrossRef
• Ginsenoside Rb1 and berberine synergistically protect against type 2 diabetes mellitus via GDF15/HAMP pathway throughout the liver lobules: Insights from spatial transcriptomics analysis
  Rongfang Guo, Shuying Zhang, Anyao Li, Ping Zhang, Xin Peng, Xiaoyan Lu, Xiaohui Fan
  Pharmacological Research.2025; 215: 107711.     CrossRef
• Factors associated with prescription of modern antidiabetics in newly diagnosed patients with type 2 diabetes. a real-world data study in a Spanish region
  Irantzu Bengoa-Urrengoechea, Isabel Aguilar-Palacio, María José Rabanaque, María Jesús Lallana, Adriana Gamba Cabezas, Sara Malo
  Frontiers in Pharmacology.2025;[Epub]     CrossRef
• Fenofibrate therapy and risk of heart failure outcomes in patients with Type 2 diabetes: a propensity-matched cohort study
  Ji Yoon Kim, Nam Hoon Kim, Jiyoon Lee, Dong-Hoon Kim, Sin Gon Kim
  European Heart Journal - Cardiovascular Pharmacotherapy.2025; 11(7): 620.     CrossRef
• High-performance liquid chromatography method for simultaneous determination of the degradation products of metformin hydrochloride and vildagliptin
  Amra Demirović, Alija Uzunović, Anisa Veledar-Hamalukić
  European Journal of Pharmaceutical Sciences.2025; 214: 107268.     CrossRef
• Cyclic amines-modified metformin derivatives with enhanced glucose uptake activity
  Muhammad Fathiy Mutalabisin, Nor Akmalyati Sulong, Nader Ghaffari Khaligh, Vannajan Sanghiran Lee, Nurshamimi Nor Rashid, Mohd Rafie Johan, Chin Fei Chee
  Results in Chemistry.2025; 18: 102830.     CrossRef
• Beta-Cell Function, Insulin Sensitivity, and Metabolic Characteristics in Young-Onset Type 2 Diabetes Mellitus: Findings from Anam Diabetes Observational Study
  Ji Yoon Kim, Jiyoon Lee, Sin Gon Kim, Nam Hoon Kim
  Diabetes & Metabolism Journal.2025; 49(6): 1287.     CrossRef
• Anti-Senescence Effect of Inhibiting Sodium-Glucose Cotransporter 2 and α-Glucosidase in a Type 2 Diabetes Mellitus Animal Model
  Serin Hong, Byung Soo Kong, Hyunsuk Lee, Young Min Cho
  Diabetes & Metabolism Journal.2025; 49(6): 1229.     CrossRef
• Targeting adipose remodeling: Synergistic mechanisms of drugs and adipose-derived stem cells in obese type 2 diabetes mellitus
  Cheng Luo, Xian-Mei Yu, Liang-Yan Hua, Mei-Qi Zeng, Hui Xu, Cheng-Zheng Duan, Shi-Yu Xu, Da Sun, Li-Ya Ye, Dong-Juan He
  World Journal of Stem Cells.2025;[Epub]     CrossRef
• Balancing Bleeding and Ischemic Risks: A Systematic Review of Dual Versus Triple Therapy After Percutaneous Coronary Intervention in Patients With Atrial Fibrillation
  Abubakar Gapizov, Ahmad Mohammad, Shivam Singla, Bhavna Singla, Saifullah Syed, Sunita Kumawat, Zulqurnain Ali
  Cureus.2025;[Epub]     CrossRef
• GLYCEMIC CONTROL AND COMORBIDITIES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: A GENDER-BASED STUDY IN HEALTH FACILITIES OF DUHOK, IRAQ
  Hozan Qasim Hussein, Hileen Mustafa Haji, Milat Hussein Mustafa
  Health Problems of Civilization.2025;[Epub]     CrossRef
• Vector of glycated hemoglobin in the formation of dysglycemia in postmenopause: Emphasis on early diagnosis and therapy
  L. A. Ruyatkina, D. S. Ruyatkin, L. V. Shcherbakova, I. S. Iskhakova
  Meditsinskiy sovet = Medical Council.2024; (16): 135.     CrossRef

Citations

Citations to this article as recorded by  

• Association between age at diagnosis of type 2 diabetes and cardiovascular morbidity and mortality risks: A nationwide population-based study
  Da Hea Seo, Mina Kim, Young Ju Suh, Yongin Cho, Seong Hee Ahn, Seongbin Hong, So Hun Kim
  Diabetes Research and Clinical Practice.2024; 208: 111098.     CrossRef
• Association between Age at Diagnosis of Type 2 Diabetes and Subsequent Risk of Dementia and Its Major Subtypes
  Da Hea Seo, Mina Kim, Yongin Cho, Seong Hee Ahn, Seongbin Hong, So Hun Kim
  Journal of Clinical Medicine.2024; 13(15): 4386.     CrossRef
• Assessment of cardiovascular risk with sulfonylurea use in type 2 diabetes mellitus: A retrospective cohort study
  Jari Delbaere, Ewoud Deboever, Bert Vaes, Frank Nobels, Pavlos Mamouris, Geert Goderis
  Primary Care Diabetes.2024; 18(6): 599.     CrossRef
• Systematic review and meta-analysis of teneligliptin for treatment of type 2 diabetes
  R. Pelluri, S. Kongara, V. R. Nagasubramanian, S. Mahadevan, J. Chimakurthy
  Journal of Endocrinological Investigation.2023; 46(5): 855.     CrossRef
• Finding the most cost-effective option from commonly used Dipeptidyl peptidase-4 inhibitors in India: a systematic study
  Harmanjit Singh, Ekta Arora, Seerat Narula, Mandeep Singla, Armaan Otaal, Jatin Sharma
  Expert Review of Endocrinology & Metabolism.2023; 18(4): 347.     CrossRef
• Association Between DPP4 Inhibitor Use and the Incidence of Cirrhosis, ESRD, and Some Cancers in Patients With Diabetes
  Yewon Na, Soo Wan Kim, Ie Byung Park, Soo Jung Choi, Seungyoon Nam, Jaehun Jung, Dae Ho Lee
  The Journal of Clinical Endocrinology & Metabolism.2022; 107(11): 3022.     CrossRef

The prevalence of type 2 diabetes mellitus (T2DM), which is associated with cardiovascular morbidity and mortality, is increasing worldwide. Although there have been advances in diabetes treatments that reduce microvascular complications (nephropathy, neuropathy, retinopathy), many clinical studies have found that conventional oral hypoglycemic agents and glucose control alone failed to reduce cardiovascular disease. Thus, incretin-based therapies including glucagon-like peptide 1 (GLP-1) receptor agonists (RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT-2Is) represent a new area of research, and may serve as novel therapeutics for treating hyperglycemia and modifying other cardiovascular risk factors. Recently, it has been confirmed that several drugs in these classes, including canagliflozin, empagliflozin, semaglutide, and liraglutide, are safe and possess cardioprotective effects. We review the most recent cardiovascular outcome trials on GLP-1RAs and SGLT-2Is, and discuss their implications for treating patients with T2DM in terms of protective effects against cardiovascular disease.

Citations

Citations to this article as recorded by  

• Retrospective real-world database study to examine the prevalence and incidence of cardiovascular diseases and medication prescription in Japanese patients with type 2 diabetes
  Mitsuhisa Komatsu, Hiroshi Kobayashi, Satoshi Tsuboi, Hirotaka Watada
  Diabetology International.2026;[Epub]     CrossRef
• Characterization of treatment intensified (add‐on to metformin) adults with type 2 diabetes in Thailand: A cross‐sectional real‐world study (CONVERGE)
  Chutintorn Sriphrapradang, Ammarin Thakkinstian, Ratiporn Chinthammit, Gurudutt Nayak
  Journal of Diabetes Investigation.2025; 16(6): 1010.     CrossRef
• Switch to gliflozins and biventricular function improvement in patients with chronic heart failure and diabetes mellitus
  Michele Correale, Pietro Mazzeo, Martino Fortunato, Matteo Paradiso, Andrea Furore, Angela I. Fanizzi, Lucia Tricarico, Giuseppe Pastore, Simona Alfieri, Natale D. Brunetti, Olga Lamacchia
  Clinical Physiology and Functional Imaging.2024; 44(1): 112.     CrossRef
• Association between underweight and risk of heart failure in diabetes patients
  Tae Kyung Yoo, Kyung‐Do Han, Eun‐Jung Rhee, Won‐Young Lee
  Journal of Cachexia, Sarcopenia and Muscle.2024; 15(2): 671.     CrossRef
• The effects of dipeptidyl peptidase-4 inhibitors on cardiac structure and function using cardiac magnetic resonance: a meta-analysis of clinical studies
  Haipeng Wang, Siyi Guo, Shuo Gu, Chunyu Li, Fei Wang, Junyu Zhao
  Frontiers in Endocrinology.2024;[Epub]     CrossRef
• Paradigm shift from glucocentric to organ protection for the management of hyperglycemia in patients with type 2 diabetes
  Jie-Eun Lee, Jong Chul Won
  Cardiovascular Prevention and Pharmacotherapy.2024; 6(4): 116.     CrossRef
• Paradigm Shift in Management of Hyperglycemia in Patients with Type 2 Diabetes: Glucocentric versus Organ Protection
  Jong Chul Won
  The Journal of Korean Diabetes.2023; 24(2): 59.     CrossRef
• Posing the rationale for synthetic lipoxin mimetics as an adjuvant treatment to gold standard atherosclerosis therapies
  Braden Millar, Monica de Gaetano
  Frontiers in Pharmacology.2023;[Epub]     CrossRef
• Improvement of Left Ventricular Global Longitudinal Strain after 6-Month Therapy with GLP-1RAs Semaglutide and Dulaglutide in Type 2 Diabetes Mellitus: A Pilot Study
  Paolo Basile, Andrea Igoren Guaricci, Giuseppina Piazzolla, Sara Volpe, Alfredo Vozza, Marina Benedetto, Maria Cristina Carella, Daniela Santoro, Francesco Monitillo, Andrea Baggiano, Saima Mushtaq, Laura Fusini, Fabio Fazzari, Cinzia Forleo, Nunziata Rib
  Journal of Clinical Medicine.2023; 12(4): 1586.     CrossRef
• Rationale and Design of the Biventricular Evaluation of Gliflozins Effects In chroNic Heart Failure: BEGIN-HF Study
  Michele Correale, Elena-Laura Antohi, Riccardo M. Inciardi, Pietro Mazzeo, Stefano Coiro, Shiro Ishihara, Renata Petroni, Francesco Monitillo, Marta Leone, Marco Triggiani, Chaudhry M.S. Sarwar, Hans-Dirk Dungen, Khawaja M. Talha, Natale D. Brunetti, Jave
  ESC Heart Failure.2023; 10(3): 2066.     CrossRef
• Effects of Incretin-Based Treatment on the Diastolic (Dys)Function in Patients with Uncontrolled Type 2 Diabetes Mellitus: A Prospective Study with 1-Year Follow-Up
  Elena-Daniela Grigorescu, Cristina-Mihaela Lăcătușu, Mariana Floria, Georgiana-Diana Cazac, Alina Onofriescu, Livia-Amira Sauciuc, Alexandr Ceasovschih, Ioana Crețu, Bogdan-Mircea Mihai, Laurențiu Șorodoc
  Diagnostics.2023; 13(17): 2817.     CrossRef
• Role of moesin in the effect of glucagon-like peptide-1 on advanced glycation end products-induced endothelial barrier dysfunction
  Yan Liu, Zhenzhen Chen, Lei Liu, Haitao Tang, Huaqing Zhu, Songtao Tang
  Cellular Signalling.2022; 90: 110193.     CrossRef
• Comparative Efficacy of Lobeglitazone Versus Pioglitazone on Albuminuria in Patients with Type 2 Diabetes Mellitus
  Kyung-Soo Kim, Sangmo Hong, Hong-Yup Ahn, Cheol-Young Park
  Diabetes Therapy.2021; 12(1): 171.     CrossRef
• Effectiveness of liraglutide 3 mg for the treatment of obesity in a real-world setting without intensive lifestyle intervention
  Jung Ha Park, Ju Young Kim, Jong Han Choi, Hye Soon Park, Hyun-Young Shin, Jae Min Lee, Jin-Wook Kim, Hae-Jin Ko, Suk Chon, Bu Kyung Kim, Chul Sik Kim, Soo Lim
  International Journal of Obesity.2021; 45(4): 776.     CrossRef
• Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure
  Shruti S Joshi, Trisha Singh, David E Newby, Jagdeep Singh
  Heart.2021; 107(13): 1032.     CrossRef
• Effects of antidiabetic drugs on left ventricular function/dysfunction: a systematic review and network meta-analysis
  Da-Peng Zhang, Li Xu, Le-Feng Wang, Hong-Jiang Wang, Feng Jiang
  Cardiovascular Diabetology.2020;[Epub]     CrossRef
• Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease
  Kyung-Soo Kim, Byung-Wan Lee
  Clinical and Molecular Hepatology.2020; 26(4): 430.     CrossRef
• Benefit-Risk Assessment of Alogliptin for the Treatment of Type 2 Diabetes Mellitus
  Kohei Kaku, Koichi Kisanuki, Mari Shibata, Takashi Oohira
  Drug Safety.2019; 42(11): 1311.     CrossRef

Diabetes is a well-known risk factor of cardiovascular morbidity and mortality, and the beneficial effect of improved glycemic control on cardiovascular complications has been well established. However, the rosiglitazone experience aroused awareness of potential cardiovascular risk associated with diabetes drugs and prompted the U.S. Food and Drug Administration to issue new guidelines about cardiovascular risk. Through postmarketing cardiovascular safety trials, some drugs demonstrated cardiovascular benefits, while some antidiabetic drugs raised concern about a possible increased cardiovascular risk associated with drug use. With the development of new classes of drugs, treatment options became wider and the complexity of glycemic management in type 2 diabetes has increased. When choosing the appropriate treatment strategy for patients with type 2 diabetes at high cardiovascular risk, not only the glucose-lowering effects, but also overall benefits and risks for cardiovascular disease should be taken into consideration.

Citations

Citations to this article as recorded by  

• Dipeptidyl peptidase-4 inhibitor compared with sulfonylurea in combination with metformin: cardiovascular and renal outcomes in a propensity-matched cohort study
  Kyoung Jin Kim, Jimi Choi, Juneyoung Lee, Jae Hyun Bae, Jee Hyun An, Hee Young Kim, Hye Jin Yoo, Ji A. Seo, Nan Hee Kim, Kyung Mook Choi, Sei Hyun Baik, Sin Gon Kim, Nam Hoon Kim
  Cardiovascular Diabetology.2019;[Epub]     CrossRef
• Sodium‐glucose cotransporter 2 inhibitors regulate ketone body metabolism via inter‐organ crosstalk
  Jin Hee Kim, Minyoung Lee, Soo Hyun Kim, So Ra Kim, Byung‐Wan Lee, Eun Seok Kang, Bong‐Soo Cha, Jin Won Cho, Yong‐ho Lee
  Diabetes, Obesity and Metabolism.2019; 21(4): 801.     CrossRef
• Glitazones and alpha-glucosidase inhibitors as the second-line oral anti-diabetic agents added to metformin reduce cardiovascular risk in Type 2 diabetes patients: a nationwide cohort observational study
  Cheng-Wei Chan, Chu-Leng Yu, Jiunn-Cherng Lin, Yu-Cheng Hsieh, Che-Chen Lin, Chen-Ying Hung, Cheng-Hung Li, Ying-Chieh Liao, Chu-Pin Lo, Jin-Long Huang, Ching-Heng Lin, Tsu-Juey Wu
  Cardiovascular Diabetology.2018;[Epub]     CrossRef
• Normoglucemiantes orales y riesgo cardiovascular
  Guillermo Guzmán, Juan Esteban Gómez, Leidy Johanna Plaza, María Claudia Sánchez
  Revista Colombiana de Cardiología.2018; 25(5): 333.     CrossRef
• Dipeptidyl peptidase-4 inhibitor use and risk of diabetic retinopathy: A population-based study
  N.H. Kim, J. Choi, N.H. Kim, K.M. Choi, S.H. Baik, J. Lee, S.G. Kim
  Diabetes & Metabolism.2018; 44(4): 361.     CrossRef
• Obesity and Type 2 Diabetes in Our Youth: A Recipe for Cardiovascular Disease
  Angela Kaye Wooton, Lynne M. Melchior
  The Journal for Nurse Practitioners.2017; 13(3): 222.     CrossRef
• Sex-gender-related therapeutic approaches for cardiovascular complications associated with diabetes
  Ilaria Campesi, Flavia Franconi, Giuseppe Seghieri, Marco Meloni
  Pharmacological Research.2017; 119: 195.     CrossRef
• The Landscape of Glucose-Lowering Therapy and Cardiovascular Outcomes: From Barren Land to Metropolis
  Mona P. Nasrallah, Charbel Abi Khalil, Marwan M. Refaat
  BioMed Research International.2017; 2017: 1.     CrossRef
• Articles inEndocrinology and Metabolismin 2016
  Won-Young Lee
  Endocrinology and Metabolism.2017; 32(1): 62.     CrossRef

Citations

Citations to this article as recorded by  

• Comparative Effectiveness of Oral Hypoglycemic Agents for Glycemic Control and Glycemic Variability in Patients with Type 2 Diabetes Mellitus: Using Flash Glucose Monitoring
  Poongothai Venkatachalapathy, Karthik Kumar Dos Alagarswamy Mohandoss, Murali Munisamy, Mohan Sellappan
  Current Diabetes Reviews.2025;[Epub]     CrossRef
• Combined assessment of stress hyperglycemia ratio and glycemic variability to predict all-cause mortality in critically ill patients with atherosclerotic cardiovascular diseases across different glucose metabolic states: an observational cohort study with
  Fuxu Wang, Yu Guo, Yuru Tang, Shuangmei Zhao, Kaige Xuan, Zhi Mao, Ruogu Lu, Rongyao Hou, Xiaoyan Zhu
  Cardiovascular Diabetology.2025;[Epub]     CrossRef
• Glycemic Variability and Gut Microbiota Metabolic Patterns: A Novel Perspective on Diabetic Complications
  Yongjie Xu, Di Chen, Huiru Yang, Yiqiong Zhang, Changyudong Huang, Yinxue Zhong, Haizhi Li, Liying Zhu, Chengcheng Li, Rui Yan, Mi Liu, Wei Pan
  Food Science & Nutrition.2025;[Epub]     CrossRef
• Prognostic value of longitudinal HbA1c variability in predicting the development of diabetic sensorimotor polyneuropathy among patients with type 2 diabetes mellitus: A prospective cohort observational study
  Yun‐Ru Lai, Wen‐Chan Chiu, Chih‐Cheng Huang, Ben‐Chung Cheng, I‐Hsun Yu, Chia‐Te Kung, Ting Yin Lin, Hui Ching Chiang, Chun‐En Aurea Kuo, Cheng‐Hsien Lu
  Journal of Diabetes Investigation.2024; 15(3): 326.     CrossRef
• Influence of dipeptidyl peptidase-4 inhibitors on glycemic variability in patients with type 2 diabetes: A meta-analysis of randomized controlled trials
  Shangyu Chai, Ruya Zhang, Ye Zhang, Richard David Carr, Yiman Zheng, Swapnil Rajpathak, Miao Yu
  Frontiers in Endocrinology.2022;[Epub]     CrossRef
• Glycemic Variability in Subjects with Diabetes and Hypogonadism during Testosterone Replacement Treatment: A Pilot Study
  Giuseppe Defeudis, Ernesto Maddaloni, Giovanni Rossini, Alfonso Maria Di Tommaso, Rossella Mazzilli, Paolo Di Palma, Paolo Pozzilli, Nicola Napoli
  Journal of Clinical Medicine.2022; 11(18): 5333.     CrossRef
• New Insights into the Role of Visit-to-Visit Glycemic Variability and Blood Pressure Variability in Cardiovascular Disease Risk
  Jin J. Zhou, Daniel S. Nuyujukian, Peter D. Reaven
  Current Cardiology Reports.2021;[Epub]     CrossRef
• Prevalence of glycemic variability and factors associated with the glycemic arrays among end-stage kidney disease patients on chronic hemodialysis
  Abdul Hanif Khan Yusof Khan, Nor Fadhlina Zakaria, Muhammad Adil Zainal Abidin, Nor Azmi Kamaruddin
  Medicine.2021; 100(30): e26729.     CrossRef
• Dipeptidyl-Peptidase-IV Inhibitors, Imigliptin and Alogliptin, Improve Beta-Cell Function in Type 2 Diabetes
  Xu Liu, Yang Liu, Hongzhong Liu, Haiyan Li, Jianhong Yang, Pei Hu, Xinhua Xiao, Dongyang Liu
  Frontiers in Endocrinology.2021;[Epub]     CrossRef
• HbA 1C variability and hypoglycemia hospitalization in adults with type 1 and type 2 diabetes: A nested case-control study
  Victor W. Zhong, Juhaeri Juhaeri, Stephen R. Cole, Christina M. Shay, Penny Gordon-Larsen, Evangelos Kontopantelis, Elizabeth J. Mayer-Davis
  Journal of Diabetes and its Complications.2018; 32(2): 203.     CrossRef
• Glucose fluctuation and the resultant endothelial injury are correlated with pancreatic β cell dysfunction in patients with coronary artery disease
  Makoto Murata, Hitoshi Adachi, Shigeru Oshima, Masahiko Kurabayashi
  Diabetes Research and Clinical Practice.2017; 131: 107.     CrossRef
• Efficacy of lifestyle interventions in patients with type 2 diabetes: A systematic review and meta-analysis
  Xiao-Li Huang, Jian-Hua Pan, Dan Chen, Jing Chen, Fang Chen, Tao-Tao Hu
  European Journal of Internal Medicine.2016; 27: 37.     CrossRef